Update: 5th April 2017
You may have seen reports on social media regarding EpiPens and withdrawals of certain batches in the US and other countries. We are continuing to monitor this issue and we are in contact with MEDA who distribute EpiPens in the UK to see if this affects batches in the UK.
We will keep you updated
Update 25th March 2017
MEDA the company who distribute EpiPens in the UK have now released a statement and shared this with the Anaphylaxis Campaign. You can read this below.
Statement from MEDA
Meda is committed to the highest standards of patient safety and product quality.
EpiPen® (Adrenaline Autoinjector) is an autoinjector containing adrenaline which is used for emergency treatment of severe allergic reaction (anaphylaxis), more than 1 million patients depend on this life-saving device in Europe.
Recently, Meda received two complaints regarding the EpiPen® 300 microgram device for lot number 5FA665 from other countries than the UK. The affected batch was distributed last year, and expires Feb-May 2017.
On the basis of an investigation conducted by the manufacturer Meridian Medical Technologies (MMT) it has been observed that there may be a very small probability in lot 5FA665 that the auto-injector may not work correctly. This voluntary recall applies ONLY to lot 5FA665.
At this time, the rest of manufactured lots are not affected. The lot number is printed onto the EpiPen® and the box.
For more information: Email: [email protected]